An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance

European Journal of Endocrinology

Volumn 154, Issue 5, 2006, Pages 715-721

  Rietveld, I ^a   Hofman, A ^a   Pols, H A P ^a   van Duijin, C M ^a   Lamberts, S W J ^a   Janssen, J A M J L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; SOMATOMEDIN C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SEX DIFFERENCE; WILD TYPE;

AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 33744545891     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02144     Document Type: Article

References (40)

1. Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. American Journal of Physiology - Renal Physiology 2004 286 F442-F450.
2. Naidoo DP. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovascular Journal of South Africa 2002 13 194-199.
3. Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W & De Santo NG. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Archives of Internal Medicine 1998 158 1933-1939.
4. Young BA, Katon WJ, Von KM, Simon GE, Lin EH, Ciechanowski PS, Bush T, Oliver M, Ludman EJ & Boyko EJ. Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study. Journal of the American Society of Nephrology 2005 16 219-228.
5. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA & Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International 2003 63 225-232.
6. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. New England Journal of Medicine 1984 310 356-360.
7. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, Hirschman GH & Myers BD. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. New England Journal of Medicine 1996 335 1636-1642.
8. Delafontaine F, Song YH & Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arteriosclerosis, Thrombosis & Vascular Biology 2004 24 435-444.
9. Bar RS, Bees M, Dake BL, Booth BA, Henley SA & Sandra A. Insulin, insulin-like growth factors, and vascular endothelium. American Journal of Medicine 1988 85 59-70.
10. Gajdusek CM, Luo Z & Mayberg MR. Sequestration and secretion of insulin-like growth factor-I by bovine aortic endothelial cells. Journal of Cellular Physiology 1993 154 192-198.
11. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovascular Research 1995 30 825-834.
12. Juul A, Scheike T, Davidsen M, Gyllenborg J & Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002 106 939-944.
13. Spallarossa P, Brunelli C, Minuto F, Caruso D, Battistini M, Caponnetto S & Cordera R. Insulin-like growth factor-I and angiographically documented coronary artery disease. American Journal of Cardiology 1996 77 200-202.
14. Flyvbjerg A. Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes. Kidney International Supplement 1997 60 S12-S19.
15. LeRoith D, Werner H, Phillip M & Roberts CT Jr. The role of insulin-like growth factors in diabetic kidney disease. American Journal of Kidney Disease 1993 22 722-726.
16. Froesch ER, Hussain MA, Schmid C & Zapf J. Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Diabetes Metabolism Reviews 1996 12 195-215.
17. Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA & van Duijn CM. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001 50 637-642.
18. Tae HJ, Luo X & Kim KH. Roles of CCAAT/enhancer-binding protein and its binding site on repression and derepression of acetyl-CoA carboxylase gene. Journal of Biological Chemistry 1994 269 10475-10484.
19. Yu H, Li BD, Smith M, Shi R, Berkel HJ & Kato I. Polymorphic CA repeats in the IGF-I gene and breast cancer. Breast Cancer Research & Treatment 2001 70 117-122.
20. Hofman A, Grobbee DE, de Jong PT & van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. European Journal of Epidemiology 1991 7 403-422.
21. Baan CA, Stolk RP, Grobbee DE, Witteman JC & Feskens EJ. Physical activity in elderly subjects with impaired glucose tolerance and newly diagnosed diabetes mellitus. American Journal of Epidemiology 1999 149 219-227.
22. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003 26 (Suppl 1) S5-S20.
23. Hermans MP, Levy JC, Morris RJ & Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999 42 678-687.
24. Stolk RP, Pols HA, Lamberts SW, de Jong PT, Hofman A & Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. American Journal of Epidemiology 1997 145 24-32.
25. Cockcroft DW & Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 31-41.
26. A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus. European Arterial Risk Policy Group on behalf of the International Diabetes Federation European Region. Diabetic Medicine 1997 14 611-621.
27. Weber JL & May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. American Journal of Human Genetics 1989 44 388-396.
28. Rietveld I, Janssen JA, Hofman A, Pols HA, van Duijn CM & Lamberts SW. A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. European Journal of Endocrinology 2003 148 171-175.
29. Rietveld I, Janssen JA, van Rossum EF, Houwing-Duistermaat JJ, Rivadeneira F, Hofman A, Pols HA, van Duijn CM & Lamberts SW. A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height. Clinical Endocrinology 2004 61 195-203.
30. Bots ML, Hofman A, de Jong PT & Grobbee DE. Common carotid intima-media thickness as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam Study. Annals of Epidemiology 1996 6 147-153.
31. Bots ML, Mulder PG, Hofman A, van Es GA & Grobbee DE. Reproducibility of carotid vessel wall thickness measurements. The Rotterdam Study. Journal of Clinical Epidemiology 1994 47 921-930.
32. Hillege HL, Fidler V, Diercks GF, van Gilst WH, De Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE & de Jong PE. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002 106 1777-1782.
33. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, Froland A, Hansen KW, Nielsen S & Pedersen MM. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995 18 572-581.
34. Mogensen CE, Viberti G, Halimi S, Ritz E, Ruilope L, Jermendy G, Widimsky J, Sareli P, Taton J, Rull J, Erdogan G, De Leeuw PW, Ribeiro A, Sanchez R, Mechmeche R, Nolan J, Sirotiakova J, Hamani A, Scheen A, Hess B, Luger A & Thomas SM. Effect of low-dose perindopril/ indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003 41 1063-1071.
35. MacLeod JM, Lutale J & Marshall SM. Albumin excretion and vascular deaths in NIDDM. Diabetologia 1995 38 610-616.
36. Mattock MB, Morrish NJ, Viberti G, Keen H, Fitzgerald AP & Jackson G. Prospective study of microalbuminuria as predictor of mortality in NIDDM. Diabetes 1992 41 736-741.
37. Schut AF, Janssen JA, Deinum J, Vergeer JM, Hofman A, Lamberts SW, Oostra BA, Pols HA, Witteman JC & van Duijn CM. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke 2003 34 1623-1627.
38. Kanwar YS, Rosenzweig LJ, Linker A & Jakubowski ML. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence. PNAS 1983 80 2272-2275.
39. Raats CJ, Van Den BJ & Berden JH. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney International 2000 57 385-400.
40. Barroso I. Genetics of Type 2 diabetes. Diabetic Medicine 2005 22 517-535.